Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
Lesokhin A, LeBlanc R, Dimopoulos MA, Capra M, Carlo-Stella C, Karlin L, Castilloux JF, Forsberg P, Parmar G, Tosikyan A, Pour L, Ribrag V, Ribolla R, Abdallah AO, Le Roux N, Dong L, van de Velde H, Mayrargue L, Lépine L, Macé S, Moreau P.
Lesokhin A, et al. Among authors: castilloux jf.
Cancer Med. 2023 May;12(9):10254-10266. doi: 10.1002/cam4.5753. Epub 2023 Mar 3.
Cancer Med. 2023.
PMID: 36866838
Free PMC article.
Clinical Trial.